Document ID: chunk:federal_register_of_legislation:F2025L00215:schedule:1:p1
Version: federal_register_of_legislation:F2025L00215
Segment Type: schedule
Provision Reference: sch 1 (pt 1/51)
Character Range: 2135–5493

Schedule 1—Amendments

National Health (Listing of Pharmaceutical Benefits) Instrument 2024 (PB 26 of 2024)
[1] Schedule 1, Part 1, after entry for Acarbose in the form Tablet 50 mg [Brand: GLYBOSAY; Maximum Quantity: 180; Number of Repeats: 5]
insert:
Acarbose  Tablet 50 mg (S19A)  Oral  Acarbose 50 mg tablets (Morningside, UK)  DZ  MP NP             90   5     90
Acarbose  Tablet 50 mg (S19A)  Oral  Acarbose 50 mg tablets (Morningside, UK)  DZ  MP NP     P14238  180  5     90

[2] Schedule 1, Part 1, after entry for Acarbose in the form Tablet 100 mg [Brand: GLYBOSAY; Maximum Quantity: 180; Number of Repeats: 5]
insert:
Acarbose  Tablet 100 mg (S19A)  Oral  Acarbose 100 mg tablets (Morningside, UK)  DZ  MP NP             90   5     90
Acarbose  Tablet 100 mg (S19A)  Oral  Acarbose 100 mg tablets (Morningside, UK)  DZ  MP NP     P14238  180  5     90

[3] Schedule 1, Part 1, entries for Adalimumab in the form Injection 40 mg in 0.4 mL pre‑filled pen [Brand: Hadlima]
omit from the column headed "Responsible Person" (all instances): OQ substitute (all instances): RF
[4] Schedule 1, Part 1, entries for Adalimumab in the form Injection 40 mg in 0.4 mL pre‑filled syringe [Brand: Hadlima]
omit from the column headed "Responsible Person" (all instances): OQ substitute (all instances): RF
[5] Schedule 1, Part 1, after entry for Adalimumab in the form Injection 80 mg in 0.8 mL pre-filled pen [Brand: Humira; Maximum Quantity: 3; Number of Repeats: 0]
insert:
Adalimumab  Injection 80 mg in 0.8 mL   Injection  Hyrimoz  SZ  MP  C12103 C12105 C12155 C12212 C14398 C14399                                                          P12103 P12105 P12155 P12212 P14398 P14399                                                          1  0     1
            pre-filled pen
Adalimumab  Injection 80 mg in 0.8 mL   Injection  Hyrimoz  SZ  MP  C15788                                                                                             P15788                                                                                             2  2     1
            pre-filled pen
Adalimumab  Injection 80 mg in 0.8 mL   Injection  Hyrimoz  SZ  MP  C11529 C15777 C15796                                                                               P11529 P15777 P15796                                                                               2  5     1
            pre-filled pen
Adalimumab  Injection 80 mg in 0.8 mL   Injection  Hyrimoz  SZ  MP  C11715 C11716 C11759 C11761 C11762 C11763 C11852 C11854 C11855 C12152 C12229 C15764 C15765 C15795  P11715 P11716 P11759 P11761 P11762 P11763 P11852 P11854 P11855 P12152 P12229 P15764 P15765 P15795  3  0     1
            pre-filled pen

[6] Schedule 1, Part 1, entries for Amoxicillin with clavulanic acid
omit:
Amoxicillin with clavulanic acid  Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 100 mL (S19A)  Oral  CLAVULIN-125F (GlaxoSmithKline, Canada)  DZ  PDP    C5833 C5894  P5833 P5894  1  0     1
Amoxicillin with clavulanic acid  Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 100 mL (S19A)  Oral  CLAVULIN-125F (GlaxoSmithKline, Canada)  DZ  MP NP  C5832 C5893  P5832 P5893  1  1     1

[7] Schedule 1, Part 1,